Motif Bio Share Discussion Threads

[apfindley] 07/4/2017 08:43

Twitter pumping. No more reason for a rise this week than there has been for 6 months. Undervalued, but the movement is purely due to ramping on twitter.

[cheshire man] 07/4/2017 08:12

Lovely spot on the chart :-)

[essential] 07/4/2017 08:06

Bought into these this am - looks like a strong chart break upwards on very high volume

[t-trader] 06/4/2017 16:18

Bit more volume coming in stateside now...NASDAQ trading has been dead in the water for a while, so good to see some volume even be it tiny in comparison with UK volume.

I think once first set of results are out of the way, US interest will be significant and could push us to many multiples of where we are now.

Link to MOTIF ADR's for those that are interested:



and historical stock prices:

[t-trader] 06/4/2017 16:15

DrMaccers, I was just being conservative with my price prediction. Long term this could be 5x, 10x bagger with FDA approval....who knows?....but still a way to go yet for those kind of values, so not going to get carried away.

[drmaccers] 06/4/2017 16:11

T-trader if the first REVIVE results are positive then it will be a hell of a lot higher than 50p. It'll likely get there pre results

[apfindley] 06/4/2017 16:02

Being pumped on twitter by the pumper dumper crew

[cudmore] 06/4/2017 15:29

A broker target price of 125p should see some action here imho.

[t-trader] 06/4/2017 14:33

Decent volume behind the recent rise in price, so expect more interest building up to results which could be anytime between now and end of June. If first trial results are successful then would expect 50p+ and this should bode well for the outcome of the second trial results later in the year.

[t-trader] 06/4/2017 13:00

Graham Lumsden (CEO of Motif Bio) reporting on Iclaprim at the recent Master Investor show.

[small crow] 05/4/2017 13:53

Intraday looks a bit more positive for a change. Here's hoping.

[blueblood] 05/4/2017 13:33

Start of rerate leading up to trial results?

[cheshire man] 04/4/2017 09:50

Broker Forecast

- finnCap issues a broker note on Motif Bio Plc Ord 1p

04 April 2017

finnCap today initiates coverage of Motif Bio Plc Ord 1p (LON:MTFB) with a buy investment rating and price target of 125p.

Story provided by StockMarketWire.com

DYOR

[buywell3] 04/4/2017 00:50

hazl16 Oct '15 - 10:02 - 546 of 987 0 0
yes you can feel the momentum building imo

[enewman36] 31/3/2017 13:50

What has woken this up from its slumber I wonder....

[t-trader] 26/3/2017 14:47

Thanks for the update Timbo.

[fightfear] 02/3/2017 10:42

Many thanks for you reply Vulgaris
Intersting

[vulgaris] 01/3/2017 22:41

Fightfear

MICs (= minimum inhibitory concentrations = lowest concentration of drug that stop the bug growing in the lab) are indeed 4 to 16-fold lower (=more potent) for tedizolid (Merck) than linezolid (generic ex Pfizer). This advantage has been spent in a lower dosage: 200 mg once a day for tedizolid vs. 600 mg twice a day. As a result the breakpoint (the MIC that defines the border between susceptible and resistant) is only 0.12 for tedizolid vs 2 or 4 mg/L for linezolid.

So, put simply, the greater potency of tedizolid is cancelled out by the lower dosage and breakpoint... Where there MAY be an advantage is in side effects. Linezolid has a reputation for affecting blood counts, also for GI disturbance and, much more rarely neuropathies. Phase III clinical trials in ABSSSI suggested fewer side effects with tedizolid, but it was only given for 6 days vs 10 for linezolid, with early (2-3 day) responses as good for both analogues. So, it's possible to upset Merck by arguing that the trial just showed that linezolid is ordinarily given for too long, not that tedizolid really has fewer side effects at all.

Overhanging everything, though, is linezolid going generic and the price coming down. That means most people will prefer it, perhaps seeing if they can shorten the course. I do wonder if tedizolid might be an option in patients who, for whatever reason, usually chronic infection, need long therapy, meaning that linezolid isn't suitable, but it hasn't been trialled for this and my view here is no more than speculative. It might also be explored in TB but, again, the work hasn't been done yet.

Far the more interesting antibiotic in Merck's stable is ceftolozane-tazobactam (Zerbaxa), which is highly potent against the great majority of Pseudomonas aeruginosa strains, including some of the carbapenem-resistant ones flagged in the WHO report.

[fightfear] 01/3/2017 21:11

Timbo: many thanks for the summary - great read as always

Vulgaris: I was wondering what your views are on Sivextro (Tedizolid phosphate) - is it a competition for Iclaprim?

Quote:
Tedizolid is a second-generation oxazolidinone derivative that is 4-to-16-fold more potent against staphylococci and enterococci compared to linezolid.

And some data:


If you could be so kind to share your opinion that would be much appreciated.
Thank you

[nilsvs] 01/3/2017 11:02

Worth a read..

[vulgaris] 28/2/2017 21:37

Clinical trials are statistically powered to show non-inferiority to 'standard of care' (which hopefully is 'effective'). It's a rare bonus if superiority is seen

[ohisay] 28/2/2017 11:49

Emphasis on effective of course - new not necessarily better..